FOL-005
Androgenetic Alopecia
Phase 2aActive
Key Facts
About Takeda
Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.
View full company profileOther Androgenetic Alopecia Drugs
| Drug | Company | Phase |
|---|---|---|
| TOP-M119 | Topadur Pharma | Phase 2 |
| AMP-303 | Amplifica | Phase 1 |
| GM-502 | Galderma Group | Phase 2 |
| GSK-3β Inhibitor (Topical) | Cosmo Pharmaceuticals | Phase II |